Patents Examined by Hong Sang
  • Patent number: 10316084
    Abstract: The invention provides anti-LgR5 antibodies and methods of using the same.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 11, 2019
    Assignee: GENENTECH, INC.
    Inventors: Andrew G. Polson, Weiguang Mao, Ron Firestein
  • Patent number: 10301385
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 28, 2019
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Patent number: 10287356
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 14, 2019
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Patent number: 10279039
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Patent number: 10279040
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Patent number: 10279038
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Patent number: 10266586
    Abstract: Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: April 23, 2019
    Assignee: The Medical College of Wisconsin, Inc.
    Inventor: Michael A. James
  • Patent number: 10251944
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: April 9, 2019
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • Patent number: 10253096
    Abstract: The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Yi Zhang, Yang Shen, Carmine Carpenito, Yiwen Li
  • Patent number: 10241113
    Abstract: Disclosed are compositions and methods for predicting responsiveness of a subject to treatment with lenalidomide (LEN) by assaying a sample from the subject for surface expression of CD28 on T-cells. Also provided is a method of treating a subject for cancer that involves assaying a sample from the subject for surface expression of CD28 on T-cells and then treating them with LEN if they do not have reduced CD28 surface expression on the T-cells. Also provided is a method for promoting responsiveness of a subject to LEN by administering to the subject a composition that promotes expression of CD28 on the surface of T-cells.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 26, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Pearlie Burnette, Jessica M. McDaniel
  • Patent number: 10239949
    Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 26, 2019
    Assignees: Aptevo Research and Development, LLC, Alligator Bioscience AB
    Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
  • Patent number: 10232038
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: March 19, 2019
    Assignee: IMMUTEP
    Inventor: Frederic Triebel
  • Patent number: 10195209
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 5, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Patent number: 10188660
    Abstract: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: January 29, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Jonathan A. Hickson, Susan Elizabeth Morgan-Lappe, James W. Purcell
  • Patent number: 10189906
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 29, 2019
    Assignee: MAX-DELRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • Patent number: 10188698
    Abstract: Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 29, 2019
    Inventor: Xiaoyang Qi
  • Patent number: 10183993
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 22, 2019
    Assignee: Lentigen Technology Inc.
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Patent number: 10175240
    Abstract: The present invention provides a method for determining a treatment procedure for breast cancer, a method of predicting a likelihood of success in treating breast cancer, and a method for selecting an endocrine therapy agent for treating breast cancer. In particular, methods of the present invention rely on the amount of androgen receptor (AR) and estrogen receptor (ER) in a tissue sample.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 8, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Jennifer Richer Mouchantat
  • Patent number: 10174106
    Abstract: The present invention relates to a neutralizing antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralizes the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralizing antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
    Inventor: Patricia Forgez
  • Patent number: 10167340
    Abstract: Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: January 1, 2019
    Assignee: Health Research, Inc.
    Inventors: Robert A. Fenstermaker, Michael J. Ciesielski